Neurocrine price target raised to $145 from $137 at RBC Capital

RBC Capital raised the firm’s price target on Neurocrine (NBIX) to $145 from $137 and keeps an Outperform rating on the shares. The company reported solid Ingrezza sales and reiterated guidance were reassuring as high patient starts and expanding access should offset what appears to be manageable price compression from contracting, the analyst tells investors in a research note. Crenessity looks to be off to a good start, even if an early bolus effect may have contributed, RBC adds.